GUMDROP : GWU - A Phase 2 Study Evaluating the Efficacy of Docetaxel in Combination With Ramucirumab or IMC-18F1 or Without Investigational Therapy as Second-line Therapy in Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder

Created by Nancy Dawson, last modified on Sep 13, 2013
Description:This multicenter trial will enroll participants with metastatic transitional cell carcinoma of the bladder, urethra, ureter, or renal pelvis who have had disease progression on first-line platinum-based chemotherapy regimens. Participants will be enrolled into 1 of 3 treatment arms: docetaxel; docetaxel and ramucirumab; or docetaxel and IMC-18F1.
Link:http://clinicaltrials.gov/ct2/show/NCT01282463
Site:George Washington University
Principle Investigator:Hiwot Guebre-Xabiher